Alliance Wealth Advisors LLC Has $302,000 Position in GSK plc (NYSE:GSK)

Alliance Wealth Advisors LLC lifted its position in shares of GSK plc (NYSE:GSK) by 23.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,918 shares of the pharmaceutical company’s stock after acquiring an additional 1,688 shares during the period. Alliance Wealth Advisors LLC’s holdings in GSK were worth $302,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in GSK. Eastern Bank bought a new position in GSK in the third quarter valued at about $26,000. Sunbelt Securities Inc. lifted its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Crews Bank & Trust bought a new stake in shares of GSK in the fourth quarter worth $26,000. Concord Wealth Partners raised its position in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the last quarter. Finally, ST Germain D J Co. Inc. grew its position in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Down 1.0 %

NYSE GSK opened at $36.03 on Friday. The business has a fifty day simple moving average of $34.25 and a 200 day simple moving average of $37.57. The firm has a market capitalization of $74.68 billion, a P/E ratio of 22.66, a PEG ratio of 1.42 and a beta of 0.64. The company has a current ratio of 0.78, a quick ratio of 0.53 and a debt-to-equity ratio of 1.12. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts predict that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.36%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s payout ratio is presently 93.08%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on GSK shares. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.